A new email from Bret Worley of MC Nutraceuticals is creating real ripples across the hemp-derived cannabinoid space, and in this episode of TDR Cannabis in 5, host Shadd Dales breaks down why the messaging doesn’t fully line up with reality once you dig into the details.Worley’s email centers on the December 11 extension written into the Senate’s base bill text, claiming it protects flower, D8, D9, HHC, and isolates as naturally derived products operating under today’s rules. The problem, Shadd points out, is that Delta-8 and HHC aren’t naturally derived, they’re synthetic conversions, and that distinction matters legally, scientifically, and for enforcement. The Senate’s protection genuinely applies to naturally derived hemp products, but it doesn’t automatically extend the same shield to synthetic conversions the way Worley’s email implies.Shadd also flags what the email leaves out entirely, this extension still has to pass once lawmakers return from recess post-Labor Day, nothing about it is locked in yet. And given that MC Nutraceuticals is one of the largest synthetic conversion producers in the country, blending naturally derived products with synthetic ones in the same breath isn’t a small detail, it’s the kind of messaging regulators, competitors, and the market are going to notice.A closer look at why precision and honesty matter more than ever as the hemp industry heads toward its next deadline.#TDRCannabisIn5 #HempIndustry #Delta8 #HHC #MCNutraceuticals #HempRegulation #CannabisPolicy #CannabisNews #HempBan #SyntheticCannabinoidsWant to see more Cannabis Reform?🎬    • Is Cannabis Rescheduling Dead on Arrival? ...  🎬    • Congress Demands Answers on Schedule III |...  🎬    • Paxton Dodges Question on Texas THC Ban | ...  🎬    • Cannabis Rescheduling Enters New Phase Nex...  Want to stay updated on Cannabis, Small Cap, AI, and Crypto?Subscribe to our Daily Baked newsletter:https://newsletter.thedalesreport.com...Find us on social media and podcast platforms:✅ Facebook:   / thedalesreport  ✅ Twitter:   / thedalesreport  ✅ Instagram:   / dalesreport  ✅ LinkedIn:   / the-dales-report  Apple Podcasts: https://tinyurl.com/TDRTradetoBlackon...Spotify: https://tinyurl.com/TDRTradeToBlackon...Website: https://thedalesreport.com/For copyright matters, contact:[email protected] Disclaimer (Financial Interests)The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the official policy or position of any company, organization, or employer. The content is provided for informational and entertainment purposes only and should not be taken as financial, investment, or legal advice.The hosts and/or guests may hold positions in the companies, stocks, or financial instruments discussed during the show. These holdings should not be considered endorsements or recommendations to buy or sell any securities. Listeners are encouraged to do their own research or consult with a qualified financial advisor before making any investment decisions.By listening to this podcast, you agree that the hosts, guests, and producers are not liable for any decisions made based on the information discussed.Full Disclosures: https://thedalesreport.com/website-te...

Could broader marijuana rescheduling actually be dead on arrival under the Trump administration? In this episode of TDR Cannabis in 5, host Shadd Dales breaks down an op-ed from Robert Mikos, a Vanderbilt law professor specializing in marijuana law, that raises real legal questions about whether the DEA’s proposal to move all marijuana to Schedule III can actually survive.Mikos argues that Trump has publicly supported medical marijuana rescheduling specifically, not necessarily loosening restrictions on adult-use cannabis, and points out that Attorney General Todd Blanche could have moved all marijuana to Schedule III back in April but chose to limit that action to medical cannabis, citing international treaty obligations. His strongest argument, if those treaty concerns genuinely block rescheduling adult-use marijuana, the same logic could block DEA’s broader rule currently working through the administrative process.Shadd walks through why he sees it differently. The treaty questions aren’t new, the administration, DOJ, and DEA have known about them throughout this entire process and kept moving forward anyway. The ALJ hearing happened, the evidentiary record was built, and DEA has now filed its final brief arguing marijuana no longer meets the criteria to stay in Schedule I. Combine that with Trump’s own public comments pushing for rescheduling to get done, and Shadd lays out why he still believes the broader effort crosses the finish line, even if legal fights over scope and adult-use treatment continue well after.#TDRCannabisIn5 #CannabisRescheduling #ScheduleIII #DEA #RobertMikos #CannabisPolicy #CannabisLaw #TrumpCannabis #CannabisNews #FederalCannabisPolicyWant to see more Cannabis Reform?🎬    • Congress Demands Answers on Schedule III |...  🎬    • Paxton Dodges Question on Texas THC Ban | ...  🎬    • Cannabis Rescheduling Enters New Phase Nex...  Want to stay updated on Cannabis, Small Cap, AI, and Crypto?Subscribe to our Daily Baked newsletter:https://newsletter.thedalesreport.com...Find us on social media and podcast platforms:✅ Facebook:   / thedalesreport  ✅ Twitter:   / thedalesreport  ✅ Instagram:   / dalesreport  ✅ LinkedIn:   / the-dales-report  Apple Podcasts: https://tinyurl.com/TDRTradetoBlackon...Spotify: https://tinyurl.com/TDRTradeToBlackon...Website: https://thedalesreport.com/For copyright matters, contact:[email protected] Disclaimer (Financial Interests)The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the official policy or position of any company, organization, or employer. The content is provided for informational and entertainment purposes only and should not be taken as financial, investment, or legal advice.The hosts and/or guests may hold positions in the companies, stocks, or financial instruments discussed during the show. These holdings should not be considered endorsements or recommendations to buy or sell any securities. Listeners are encouraged to do their own research or consult with a qualified financial advisor before making any investment decisions.By listening to this podcast, you agree that the hosts, guests, and producers are not liable for any decisions made based on the information discussed.Full Disclosures: https://thedalesreport.com/website-te...

James Yamanaka, CEO of Organigram Global (NASDAQ: OGI), logs on to break down record Q3 fiscal 2026 results, net revenue of $105.8 million, up 49% year-over-year, and net income of $76.2 million, or $0.56 per share. Adjusted EBITDA surged 136% to $13.4 million, with the newly consolidated Sanity Group in Germany contributing roughly €25 million in net revenue. Organigram continues to hold the top overall market share position in Canada, leading in vapes and milled flower, with strong positions across concentrates, flower, and pre-rolls. Shadd and James also get into European expansion progress, the EU-GMP certification update for the Moncton facility, and James’s take on Curaleaf’s (TSX: CURA) hostile takeover bid for Aurora Cannabis (NASDAQ: ACB), which sent a flurry of trading volume through several Canadian LPs, including Organigram, last week, along with where he sees M&A heading across the sector right now.Then in segment two, Adam Stettner, CEO of FundCanna, logs on again for his weekly appearance to talk emerging medical markets across the country and the lending demand growing alongside them. With medical cannabis rescheduled back in spring 2026, patient growth is expanding not just in legacy markets but newer ones like Georgia and Kentucky. Adam shares his read on what’s actually driving lending activity for cannabis operators on the medical side right now.#TradeToBlack #Organigram #OGI #Curaleaf #AuroraCannabis #FundCanna #CannabisEarnings #CannabisLending #MedicalCannabis #Flowhub #CannabisStocks #CannabisIndustry #MSOSWant to see more Cannabis Reform?🎬    • Congress Demands Answers on Schedule III |...  🎬    • Paxton Dodges Question on Texas THC Ban | ...  🎬    • Cannabis Rescheduling Enters New Phase Nex...  Want to stay updated on Cannabis, Small Cap, AI, and Crypto?Subscribe to our Daily Baked newsletter:https://newsletter.thedalesreport.com...Find us on social media and podcast platforms:✅ Facebook:   / thedalesreport  ✅ Twitter:   / thedalesreport  ✅ Instagram:   / dalesreport  ✅ LinkedIn:   / the-dales-report  Apple Podcasts: https://tinyurl.com/TDRTradetoBlackon...Spotify: https://tinyurl.com/TDRTradeToBlackon...Website: https://thedalesreport.com/For copyright matters, contact:[email protected] Disclaimer (Financial Interests)The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the official policy or position of any company, organization, or employer. The content is provided for informational and entertainment purposes only and should not be taken as financial, investment, or legal advice.The hosts and/or guests may hold positions in the companies, stocks, or financial instruments discussed during the show. These holdings should not be considered endorsements or recommendations to buy or sell any securities. Listeners are encouraged to do their own research or consult with a qualified financial advisor before making any investment decisions.By listening to this podcast, you agree that the hosts, guests, and producers are not liable for any decisions made based on the information discussed.Full Disclosures: https://thedalesreport.com/website-te...

Four members of Congress are demanding answers on how Schedule III actually works. In this episode of TDR Cannabis in 5, presented by Flowhub, host Shadd Dales breaks down a letter sent by Dina Titus, David Joyce, Ilhan Omar, and Greg Steube to President Trump, HHS Secretary Robert F. Kennedy Jr., Treasury Secretary Scott Bessent, and Attorney General Todd Blanche, asking for clarity on the DOJ’s April move shifting FDA-approved and state-licensed medical marijuana to Schedule III while adult-use cannabis remains Schedule I.He walks through the real questions raised, what protections medical patients actually have under federal law, whether home-grown medical cannabis qualifies as Schedule III, whether Medicare or private insurers could eventually cover state-dispensary cannabis, and how 280E applies to vertically integrated operators running both medical and adult-use business under one roof. There’s also a breakdown of the DEA registration questions, what happens to unregistered state-licensed operators, and what data DEA might collect in the process.The irony gets pointed out too, several of these lawmakers have been part of the Congressional Cannabis Caucus for years without passing the federal legislation that could resolve most of this confusion in the first place. Many of these questions could become irrelevant entirely if broader reform like the STATES 2.0 Act eventually passes.A sharp look at Washington asking for clarity on a mess it largely created.#TDRCannabisIn5 #CannabisRescheduling #ScheduleIII #CongressionalCannabisCaucus #CannabisPolicy #280E #STATES2Act #CannabisNews #FederalCannabisPolicy #DEAWant to see more Cannabis Reform?🎬    • Paxton Dodges Question on Texas THC Ban | ...  🎬    • Cannabis Rescheduling Enters New Phase Nex...  🎬    • Texas Hemp Crackdown Sparks Donor Influenc...  🎬    • Congress Moves to Keep Hemp‑THC Drinks Leg...  Want to stay updated on Cannabis, Small Cap, AI, and Crypto?Subscribe to our Daily Baked newsletter:https://newsletter.thedalesreport.com...Find us on social media and podcast platforms:✅ Facebook:   / thedalesreport  ✅ Twitter:   / thedalesreport  ✅ Instagram:   / dalesreport  ✅ LinkedIn:   / the-dales-report  Apple Podcasts: https://tinyurl.com/TDRTradetoBlackon...Spotify: https://tinyurl.com/TDRTradeToBlackon...Website: https://thedalesreport.com/For copyright matters, contact:[email protected] Disclaimer (Financial Interests)The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the official policy or position of any company, organization, or employer. The content is provided for informational and entertainment purposes only and should not be taken as financial, investment, or legal advice.The hosts and/or guests may hold positions in the companies, stocks, or financial instruments discussed during the show. These holdings should not be considered endorsements or recommendations to buy or sell any securities. Listeners are encouraged to do their own research or consult with a qualified financial advisor before making any investment decisions.By listening to this podcast, you agree that the hosts, guests, and producers are not liable for any decisions made based on the information discussed.Full Disclosures: https://thedalesreport.com/website-te...

In our latest Trade to Black, presented by Flowhub, hosts Shadd Dales and Anthony Varrell break down the latest twist in the Curaleaf-Aurora hostile takeover bid situation, plus a hemp email making the rounds that isn’t quite as clean as it sounds.Aurora Cannabis (TSX: ACB) (NASDAQ: ACB) responded today to Curaleaf’s (TSX: CURA) (OTCQX: CURLF) hostile takeover bid, with Executive Chairman and CEO Miguel Martin urging shareholders to take no action while a special committee reviews the $4.00 per share offer. Martin pushed back on Curaleaf’s claim that Aurora refused to engage privately, and accused Curaleaf of going public with the bid specifically to pressure shareholders into a short-term decision. They then switch to an email sent by Brett Worley, CEO of MC Nutraceuticals, claiming hemp’s protection is now written into the Senate’s base bill text through December 11. Shadd and Anthony break down what’s accurate and what’s being oversold, including the fact that D8 and HHC aren’t naturally derived cannabinoids.Kyle Sherman, CEO of Flowhub, drops in to weigh in everything and talk about their new Text-to-Order AI feature: https://www.flowhub.com/tools/text-to....In the final segment, the show continues with the weekly Vantage Standard segment with COO Deepank Utkhede and Director of Sales Christian Santi. This week centers on Vantage’s extension of its TGA approval in Australia, not a new approval, but proof of an already-trusted, ongoing relationship with one of the toughest regulators in the world. They break down what CGMP compliance actually demands on a continuous basis, how certifications like TGA, ICH Q7, and a DEA Schedule I license each unlock access to different high-barrier global markets, and why that positions Vantage as a genuine partner of choice for major pharmaceutical players looking for reliable cannabinoid manufacturing partners.#TradeToBlack #AuroraCannabis #Curaleaf #MiguelMartin #HempIndustry #Flowhub #Vantage #CannabisMA #CannabisNews #HempRegulationWant to see more Cannabis Reform?🎬    • Paxton Dodges Question on Texas THC Ban | ...  🎬    • Cannabis Rescheduling Enters New Phase Nex...  🎬    • Texas Hemp Crackdown Sparks Donor Influenc...  🎬    • Congress Moves to Keep Hemp‑THC Drinks Leg...  Want to stay updated on Cannabis, Small Cap, AI, and Crypto?Subscribe to our Daily Baked newsletter:https://newsletter.thedalesreport.com...Find us on social media and podcast platforms:✅ Facebook:   / thedalesreport  ✅ Twitter:   / thedalesreport  ✅ Instagram:   / dalesreport  ✅ LinkedIn:   / the-dales-report  Apple Podcasts: https://tinyurl.com/TDRTradetoBlackon...Spotify: https://tinyurl.com/TDRTradeToBlackon...Website: https://thedalesreport.com/For copyright matters, contact:[email protected] Disclaimer (Financial Interests)The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the official policy or position of any company, organization, or employer. The content is provided for informational and entertainment purposes only and should not be taken as financial, investment, or legal advice.The hosts and/or guests may hold positions in the companies, stocks, or financial instruments discussed during the show. These holdings should not be considered endorsements or recommendations to buy or sell any securities. Listeners are encouraged to do their own research or consult with a qualified financial advisor before making any investment decisions.By listening to this podcast, you agree that the hosts, guests, and producers are not liable for any decisions made based on the information discussed.Full Disclosures: https://thedalesreport.com/website-te...

Shadd caught up with Dan Ahrens, Managing Director and COO of AdvisorShares and the portfolio manager behind MSOS, to talk through how they actually got here, the early skepticism around building a U.S.-only cannabis fund, the total return swap structure they had to invent to make it work, and what it means now that Wall Street’s finally paying attention. From there, Shadd worked the floor grabbing reactions from a who’s who of the industry, Todd Harrison of CB1 Capital, George Archos and Aaron Miles of Verano (OTCQX: VRNOF), Trent Woloveck of Jushi Holdings (OTCQX: JUSHF), Jason Wild of TerrAscend (TSX: TSND), and AdvisorShares founder and CEO Noah Hamman, the guy who built this whole thing from scratch back in 2020.Everyone had a slightly different take, but the theme was the same, this is one more incremental step, but a real one, toward cannabis finally getting taken seriously by mainstream capital. There’s still plenty ahead, ALJ hearing briefs, Treasury guidance on 280E, more companies expected to uplist this fall, but for one Monday morning at least, cannabis got to ring the bell.#TradeToBlack #MSOS #AdvisorShares #NYSE #CannabisETF #CannabisInvesting #Verano #Jushi #TerrAscend #CannabisNews #CannabisStocks #CannabisIndustry #MSOSWant to see more Cannabis Reform?🎬    • Paxton Dodges Question on Texas THC Ban | ...  🎬    • Cannabis Rescheduling Enters New Phase Nex...  🎬    • Texas Hemp Crackdown Sparks Donor Influenc...  🎬    • Congress Moves to Keep Hemp‑THC Drinks Leg...  Want to stay updated on Cannabis, Small Cap, AI, and Crypto?Subscribe to our Daily Baked newsletter:https://newsletter.thedalesreport.com...Find us on social media and podcast platforms:✅ Facebook:   / thedalesreport  ✅ Twitter:   / thedalesreport  ✅ Instagram:   / dalesreport  ✅ LinkedIn:   / the-dales-report  Apple Podcasts: https://tinyurl.com/TDRTradetoBlackon...Spotify: https://tinyurl.com/TDRTradeToBlackon...Website: https://thedalesreport.com/For copyright matters, contact:[email protected] Disclaimer (Financial Interests)The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the official policy or position of any company, organization, or employer. The content is provided for informational and entertainment purposes only and should not be taken as financial, investment, or legal advice.The hosts and/or guests may hold positions in the companies, stocks, or financial instruments discussed during the show. These holdings should not be considered endorsements or recommendations to buy or sell any securities. Listeners are encouraged to do their own research or consult with a qualified financial advisor before making any investment decisions.By listening to this podcast, you agree that the hosts, guests, and producers are not liable for any decisions made based on the information discussed.Full Disclosures: https://thedalesreport.com/website-te...

In this episode of Trade to Black, presented by Flowhub, hosts Shadd Dales and Anthony Varrell launch a new weekly segment called the Check-In Poll of the Week, presented by NuggMD.The crew shares fresh poll data on how the hemp-THC ban is actually affecting patients on the ground. The results show a real mix, roughly 50% of respondents got their medical cannabis card as a result, 8% had trouble finding products, 20% reported no real impact at all, and 8% said they weren’t even aware the state-level changes were happening. It’s a snapshot of how unevenly this policy shift is landing across the patient population.In segment two, accredited cannabis investor Marc Cohodes returns to make his case for why he doesn’t think the hemp ban actually goes through, and why he expects regulation instead. He walks through the reasoning behind that view and what a realistic regulatory framework could actually look like. Shadd and Anthony also get his take on Glass House Brands’ (NYSE: GLAS) latest earnings, which came with rising costs and margin compression, and how that quarter fits into his broader investment thesis on the company.A wide-ranging episode covering both the consumer side and the investment side of where hemp and cannabis policy stand right now.#TradeToBlack #CannabisPolicy #HempBan #NuggMD #MarcCohodes #GlassHouseBrands #CannabisNews #HempIndustry #CannabisInvesting #Flowhub #CannabisIndustry #Cannabis #CannabisStocks #MSOSWant to see more Cannabis Reform?🎬    • Paxton Dodges Question on Texas THC Ban | ...  🎬    • Cannabis Rescheduling Enters New Phase Nex...  🎬    • Texas Hemp Crackdown Sparks Donor Influenc...  🎬    • Congress Moves to Keep Hemp‑THC Drinks Leg...  Want to stay updated on Cannabis, Small Cap, AI, and Crypto?Subscribe to our Daily Baked newsletter:https://newsletter.thedalesreport.com...Find us on social media and podcast platforms:✅ Facebook:   / thedalesreport  ✅ Twitter:   / thedalesreport  ✅ Instagram:   / dalesreport  ✅ LinkedIn:   / the-dales-report  Apple Podcasts: https://tinyurl.com/TDRTradetoBlackon...Spotify: https://tinyurl.com/TDRTradeToBlackon...Website: https://thedalesreport.com/For copyright matters, contact:[email protected] Disclaimer (Financial Interests)The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the official policy or position of any company, organization, or employer. The content is provided for informational and entertainment purposes only and should not be taken as financial, investment, or legal advice.The hosts and/or guests may hold positions in the companies, stocks, or financial instruments discussed during the show. These holdings should not be considered endorsements or recommendations to buy or sell any securities. Listeners are encouraged to do their own research or consult with a qualified financial advisor before making any investment decisions.By listening to this podcast, you agree that the hosts, guests, and producers are not liable for any decisions made based on the information discussed.Full Disclosures: https://thedalesreport.com/website-te...

Could Texas turn blue over a fight about THC? In this episode of TDR Cannabis in 5, host Shadd Dales breaks down a story first reported by Marijuana Moment involving Texas Democrat James Talarico, Attorney General and Senate candidate Ken Paxton, and an unexpected voice weighing in, Joe Rogan.A video circulating on X shows Paxton being directly asked about his thoughts on the state’s THC ban, and he doesn’t answer. Talarico is using that silence to double down on an earlier claim that Paxton has been shaping cannabis policy around donor dollars, an allegation Paxton’s office hasn’t publicly addressed. Shadd walks through why that moment is getting so much attention and what it says about where cannabis policy stands in a state that rarely puts it front and center.Rogan, who lives in Texas and has one of the largest platforms in the country, added his own warning, that pushing too hard on THC restrictions could actually cost Republicans politically in the state. Shadd gets into why that combination, a Senate candidate dodging the question and a major national voice weighing in, signals just how mainstream this issue has become, and what it means for a state with one of the largest hemp and THC consumer bases in the country heading into a heated election cycle.A closer look at how cannabis politics are playing out in one of the country’s biggest battleground conversations.#TDRCannabisIn5 #TexasPolitics #JamesTalarico #KenPaxton #JoeRogan #THCBan #CannabisPolicy #TexasHemp #CannabisNews #Election2026 #CannabisIndustry #CannabisReschedulingWant to see more Cannabis Reform?🎬    • Cannabis Rescheduling Enters New Phase Nex...  🎬    • Texas Hemp Crackdown Sparks Donor Influenc...  🎬    • Congress Moves to Keep Hemp‑THC Drinks Leg...  Want to stay updated on Cannabis, Small Cap, AI, and Crypto?Subscribe to our Daily Baked newsletter:https://newsletter.thedalesreport.com...Find us on social media and podcast platforms:✅ Facebook:   / thedalesreport  ✅ Twitter:   / thedalesreport  ✅ Instagram:   / dalesreport  ✅ LinkedIn:   / the-dales-report  Apple Podcasts: https://tinyurl.com/TDRTradetoBlackon...Spotify: https://tinyurl.com/TDRTradeToBlackon...Website: https://thedalesreport.com/For copyright matters, contact:[email protected] Disclaimer (Financial Interests)The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the official policy or position of any company, organization, or employer. The content is provided for informational and entertainment purposes only and should not be taken as financial, investment, or legal advice.The hosts and/or guests may hold positions in the companies, stocks, or financial instruments discussed during the show. These holdings should not be considered endorsements or recommendations to buy or sell any securities. Listeners are encouraged to do their own research or consult with a qualified financial advisor before making any investment decisions.By listening to this podcast, you agree that the hosts, guests, and producers are not liable for any decisions made based on the information discussed.Full Disclosures: https://thedalesreport.com/website-te...

In our latest Trade To Black podcast presented by Flowhub, hosts Shadd Dales and Anthony Varrell break down the chaos that's happening on the political front in Texas involving, what else? Hemp! Democrat James Talarico is calling out Republican Senate candidate and current Attorney General Ken Paxton over his refusal to answer a question about the state’s THC ban. The party is also pointing to comments from podcaster Joe Rogan, who warned Republicans that cracking down too aggressively on THC products could flip Texas blue. A video posted to X shows Paxton being asked directly about the “state’s THC ban,” and the clip has already sparked national attention.Then in Segment #1, Sammy Armenia, Director of Capital Markets at Vireo Growth (CSE: VREO) (OTCQX: VREOF), joins us to walk through the company’s Q2 2026 results. Vireo reported $209.3M GAAP revenue, up 335% year‑over‑year, with adjusted EBITDA of $41.5M, nearly breakeven net income, and a cash position of $122.7M. With acquisitions including Hawthorne, Eaze, and Bridgewell — and more on the way — Vireo is positioning itself as one of the largest operators in the country.In Segment #2, Michael Bronstein, President of the American Trade Association for Cannabis & Hemp, logs on to break down today’s federal briefing deadline for cannabis rescheduling. The ALJ now moves into the administrative phase, and we get his take on what a realistic timeline looks like for feedback from the summer hearings.The moment has arrived — and cannabis is front and center.Like, subscribe, and leave your comments!#CannabisNews #TradeToBlack #Flowhub #CannabisRescheduling #TexasPolitics #THCPolicy #VireoGrowth #CannabisEarnings #CannabisIndustry #TDRPodcast #CannabisStocks HempBan #JoeRogan Want to see more Cannabis Reform?🎬    • Cannabis Rescheduling Enters New Phase Nex...  🎬    • Texas Hemp Crackdown Sparks Donor Influenc...  🎬    • Congress Moves to Keep Hemp‑THC Drinks Leg...  Want to stay updated on Cannabis, Small Cap, AI, and Crypto?Subscribe to our Daily Baked newsletter:https://newsletter.thedalesreport.com...Find us on social media and podcast platforms:✅ Facebook:   / thedalesreport  ✅ Twitter:   / thedalesreport  ✅ Instagram:   / dalesreport  ✅ LinkedIn:   / the-dales-report  Apple Podcasts: https://tinyurl.com/TDRTradetoBlackon...Spotify: https://tinyurl.com/TDRTradeToBlackon...Website: https://thedalesreport.com/For copyright matters, contact:[email protected] Disclaimer (Financial Interests)The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the official policy or position of any company, organization, or employer. The content is provided for informational and entertainment purposes only and should not be taken as financial, investment, or legal advice.The hosts and/or guests may hold positions in the companies, stocks, or financial instruments discussed during the show. These holdings should not be considered endorsements or recommendations to buy or sell any securities. Listeners are encouraged to do their own research or consult with a qualified financial advisor before making any investment decisions.By listening to this podcast, you agree that the hosts, guests, and producers are not liable for any decisions made based on the information discussed.Full Disclosures: https://thedalesreport.com/website-te...

In the latest Trade To Black Podcast, host Shadd Dales sits down with MariMed (OTCQX: MRMD) CEO Jon Levine and Chief Commercial Officer Ryan Crandall to walk through the company’s Q2 2026 performance and the momentum building across U.S. cannabis.MariMed reported $41.9 million in Q2 2026 revenue, up 6% year‑over‑year, along with positive cash flow and 26 consecutive quarters of positive adjusted EBITDA. As Jon explains, “We built out every one of our facilities and kitchens with GMP to make sure that we’re compliant with the future for the Food and Drug Administration.”The episode highlights how MariMed held 40% margins in a price‑compressed environment through tighter cultivation controls, stronger manufacturing discipline, and steady retail execution. Ryan breaks down the company’s brand momentum, noting that MariMed’s portfolio grew 70 basis points faster than the broader industry and now reaches 85% of available storefronts. As he puts it, “Our teams are laser focused on what’s coming next… our brands aren’t getting left behind.”The episode also covers DEA inspections, GMP preparation, packaging inconsistencies across states, and how rescheduling could potentially change interstate commerce, medical research, and brand consistency.A strong Q2 2026, a clear plan, and a company positioning itself for the next phase of U.S. cannabis.#TradeToBlack #MariMed #CannabisNews #CannabisStocks #CannabisEarnings #CannabisRetail #CannabisBrands #CannabisRescheduling #TDRPodcast #CannabisIndustryWant to see more Cannabis Reform?🎬    • Cannabis Rescheduling Enters New Phase Nex...  🎬    • Texas Hemp Crackdown Sparks Donor Influenc...  🎬    • Congress Moves to Keep Hemp‑THC Drinks Leg...  Want to stay updated on Cannabis, Small Cap, AI, and Crypto?Subscribe to our Daily Baked newsletter:https://newsletter.thedalesreport.com...Find us on social media and podcast platforms:✅ Facebook:   / thedalesreport  ✅ Twitter:   / thedalesreport  ✅ Instagram:   / dalesreport  ✅ LinkedIn:   / the-dales-report  Apple Podcasts: https://tinyurl.com/TDRTradetoBlackon...Spotify: https://tinyurl.com/TDRTradeToBlackon...Website: https://thedalesreport.com/For copyright matters, contact:[email protected] Disclaimer (Financial Interests)The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the official policy or position of any company, organization, or employer. The content is provided for informational and entertainment purposes only and should not be taken as financial, investment, or legal advice.The hosts and/or guests may hold positions in the companies, stocks, or financial instruments discussed during the show. These holdings should not be considered endorsements or recommendations to buy or sell any securities. Listeners are encouraged to do their own research or consult with a qualified financial advisor before making any investment decisions.By listening to this podcast, you agree that the hosts, guests, and producers are not liable for any decisions made based on the information discussed.Full Disclosures: https://thedalesreport.com/website-te...